Related Experiment Video
Updated: Jan 21, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?
Melissa Bersanelli1, Roberto Iacovelli2, Sebastiano Buti3
1Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Department of Medicine and Surgery, University of Parma, Parma, Italy.
Background:
From 10% to 26% of patients with metastatic renal cell carcinoma (mRCC) experience rapidly progressive disease (PD) on treatment with sunitinib.
Objective:
To investigate the benefit of subsequent treatment with another tyrosine kinase inhibitor (TKI) or a mammalian target of rapamycin (mTOR) inhibitor in such primary refractory patients.
Design, Setting, And Participants:
A total of 150 mRCC patients with rapidly PD on first-line sunitinib (within two cycles, n=93, or four cycles, n=57) were identified: median age 59yr; nephrectomy 86%; histological subtypes: clear cell (77.8%), papillary (14%), and sarcomatoid features (18%); according to the Memorial Sloan-Kettering Cancer Center and French classifications: good risk (11% and 7%, respectively), intermediate (68% and 63%, respectively), and poor (21% and 29%, respectively).
Outcome Measurements And Statistical Analysis:
Data were retrospectively collected by a questionnaire from 19 European oncology centers between March 2005 and March 2011. Progression-free survival (PFS) and overall survival (OS) were calculated (Kaplan-Meier method).
Results And Limitations:
Median OS from the start of first-line treatment was 7.4mo. Second-line treatment was administered to 86 (57%) patients (44 mTOR inhibitors: 23 everolimus and 21 temsirolimus; 39 TKIs alone or in combination; three chemotherapy). Second-line PFS was not significantly different between TKIs and mTOR inhibitors (2.0 vs 0.9mo; p=0.536). Median OS from the start of second-line treatment was 5.0mo for mTOR inhibitors and 6.6mo for TKIs (p=0.15).
Conclusions:
Treatment with further TKIs or mTOR inhibitors for mRCC patients primarily refractory to first-line sunitinib in the observed time period achieved very minimal benefit, suggesting avoiding TKI rechallenge and possibly preferring alternative strategies, such as immune checkpoint inhibitors, after PD to a treatment line including a TKI in this setting.
Patient Summary:
The present work collected data about 150 patients affected by metastatic renal cell carcinoma, who received one of the current standard of care as first-line treatment, namely, the antiangiogenic drug sunitinib, and experienced rapid worsening of the disease. We investigated and described the subsequent outcome of such patients treated with two different types of drug, administered as second-line therapy, to better understand the best strategy to adopt for patients who got no benefit from sunitinib and to describe the current therapeutic approach in such cases.
Insights
For metastatic renal cell carcinoma patients rapidly progressing on sunitinib, subsequent treatment with tyrosine kinase inhibitors or mTOR inhibitors showed minimal benefit. Alternative strategies like immune checkpoint inhibitors may be preferable after progression.
Area of Science:
- Oncology
- Medical Research
- Pharmacology
Background:
- 10% to 26% of metastatic renal cell carcinoma (mRCC) patients exhibit rapid progression (PD) on sunitinib.
- Primary refractory disease to first-line sunitinib necessitates investigation into subsequent treatment efficacy.
Purpose of the Study:
- To evaluate the benefit of second-line tyrosine kinase inhibitors (TKIs) or mammalian target of rapamycin (mTOR) inhibitors in mRCC patients with rapid PD on sunitinib.
- To inform optimal treatment strategies for patients refractory to initial antiangiogenic therapy.
Main Methods:
- Retrospective analysis of 150 mRCC patients with rapid PD on first-line sunitinib across 19 European centers (2005-2011).
- Patients received second-line treatment with mTOR inhibitors (everolimus, temsirolimus) or TKIs.
- Progression-free survival (PFS) and overall survival (OS) were calculated using Kaplan-Meier method.
Main Results:
- Median OS from first-line treatment start was 7.4 months.
- Second-line treatment included mTOR inhibitors (n=44) or TKIs (n=39).
- No significant difference in second-line PFS (2.0 vs 0.9 months) or OS (5.0 vs 6.6 months) between mTOR inhibitors and TKIs.
Conclusions:
- Subsequent TKI or mTOR inhibitor therapy offers minimal benefit for mRCC patients refractory to first-line sunitinib.
- Rechallenging with TKIs is not recommended; consider alternative strategies like immune checkpoint inhibitors post-progression.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:20Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
01:23Renal Clearance
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...
01:08Renal Drug Clearance: Comparison Between Renal Excretion Methods
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...